[EN] COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF [FR] COMPOSÉ COMME INHIBITEUR DE LA VOIE DE SIGNALISATION WNT, COMPOSITION ET UTILISATION ASSOCIÉE
[EN] TAM KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES TAM
申请人:SYROS PHARMACEUTICALS INC
公开号:WO2019014513A1
公开(公告)日:2019-01-17
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R
1
, R
2
, R
3
, X, Y, Z, A, B, G
1
, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
[EN] BICYCLIC INHIBITORS OF ALK<br/>[FR] INHIBITEURS BICYCLIQUES DE L'ALK
申请人:ABBOTT LAB
公开号:WO2012097682A1
公开(公告)日:2012-07-26
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
[EN] BICYCLIC INHIBITORS OF ANAPHASTIC LYMPHOMA KINASE<br/>[FR] INHIBITEURS BICYCLIQUES DE LA KINASE DES LYMPHOMES ANAPLASIQUES
申请人:ABBOTT LAB
公开号:WO2012097479A1
公开(公告)日:2012-07-26
Disclosed are compounds of formula (Ⅰ) and their pharmaceutical acceptable salts, wherein R1, R2, R3, X, Y, Z, A, B, G1, m and n are defined in the description. The compositions containing the said compounds used for inhibiting kinases such as anaphastic lymphoma kinase (ALK) and methods of treating diseases such as cancer are disclosed.
Compound as WNT Signaling Inhibitor, Composition, and Use Thereof
申请人:An Songzhou
公开号:US20150119387A1
公开(公告)日:2015-04-30
The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.